The effect of budesonide on the immediate reaction to allergen challenge - a rhinomanometric study.
In a nasal allergen challenge test, the effect of the glucocorticosteroid budesonide on the pollen allergic type I reaction was investigated. Placebo and two different doses of budesonide were given intranasally for one week before the challenge. The study was designed as a double-blind cross-over trial. Treatment for one week with the active steroid significantly reduced the nasal secretion compared with placebo, as measured with the aid of a symptom score, and significantly reduced the induced nasal blockage measured objectively by rhinomanometry. No difference was found between the two doses of budesonide, 400 micrograms and 100 micrograms daily, used in the study.
D000293:Adolescent; D000328:Adult; D019819:Budesonide; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy*; D008297:Male; D008365:Manometry; D009299:Nasal Provocation Tests; D011282:Pregnenediones / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D011282:Pregnenediones; D019819:Budesonide